北京依生兴业科技有限公司 Yisheng Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement 2024-10-29 20:30
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine 2024-10-25 20:30
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance 2024-10-08 20:30
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation 2024-09-27 19:00
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 2024-09-10 20:00
LakeShore Biopharma Announces Leadership Transitions 2024-09-04 20:00
LakeShore Biopharma Announces Leadership Transitions 2024-09-04 20:00
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 2024-08-15 20:30
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition 2024-07-05 19:00
YS Biopharma Announces Name Change to LakeShore Biopharma 2024-05-24 19:30
YS Biopharma Announces Results of Extraordinary General Meeting 2024-05-22 04:15
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer 2024-05-08 04:20
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule 2024-04-29 20:00
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule 2024-04-29 20:00
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 2024-04-19 19:00
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine 2024-04-18 20:00
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 2024-04-16 20:00
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine 2024-04-09 20:00
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility 2024-04-03 20:00
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries 2024-03-05 21:00
1 2 3 4